Clinical Trial

Quantitative 3D UltraSound Brain Imaging: Development of New Bedside Biomarkers to Better Predict Neurodevelopmental Outcomes in Preterm Infants

Study acronym: QUSBI
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Prematurity is a leading cause of neurodevelopmental disorders (NDDs) tightly associated with white matter damage, including punctate white matter lesions (PWMLs). Hence, an improved detection of brain injury early in life in infants born very preterm is a top priority to predict NDDs and therefore to assess potential neuroprotective strategies and implement early interventions. 3D and quantitative tools at the bedside using ultrasound are expected to better detect and quantify not only PWMLs but also other brain structures with promising prognostic value to predict NDDs at 2 years of age.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-14.
Trial Details
NCT Number NCT07358819
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Conditions Very Preterm Infants Born < 30 Weeks of Gestation
Enrollment 360 participants
Start Date 2026-04
Primary Completion 2026-12 (estimated)
Study Completion 2031-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-18